Invivyd Inc IVVD

Healthcare Biotechnology

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

NDAQ:IVVD - Post by User

Invivyd Inc

<< Previous

Bullboard Posts

Next >>

Post by Humaniston Jan 13, 2022 9:39am

80 Views

Post# 34312142

ADGI COVID-19 ANTIBODY NEUTRALIZING ACTIVITY.......

Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies

Vandana Singh , Benzinga Staff Writer FOLLOW
January 13, 2022 7:08am 1 min read Comments
Adagio Therapeutics Inc
ADGI +0%
(Get Free Alerts for ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron variant.

Adagio shares lost almost 80% after it announced a greater than 300-fold reduction in neutralizing activity of ADG20 against omicron.
Recently published in vitro studies examined the neutralization potencies of large panels of mAbs against the omicron variant.
Findings across all three studies show that among mAbs in late-stage development or Emergency Use Authorization (EUA), ADG20 is one of only a few mAbs that demonstrated neutralizing activity against omicron.
Across two distinct, authentic neutralization assays against omicron, the data show that ADG20 had an IC50, a measurement of neutralization potency, of approximately 0.4 to 1.1 µg/mL, comparable with Xevudy (sotrovimab) and AstraZeneca Plc's

AZN +0%
(Get Free Alerts for AZN) AZD7742.

Sotrovimab is a COVID-19 monoclonal antibody therapy developed by GlaxoSmithKline plc

GSK -0.02%
and Vir Biotechnology Inc
VIR +0%
.

Adagio is evaluating ADG20 in its two global Phase 2/3 trials to prevent and treat COVID-19.
Adagio is engaging with the FDA regarding potential protocol updates to its global Phase 2/3 trials, including an increased dose of ADG20. The Company has paused enrollment in the 300 mg dose arm.
Adagio is exploring the potential to engineer ADG20 to improve binding to the omicron variant for enhanced neutralization potency while retaining its neutralization against other variants.
These efforts are underway, and the Company anticipates preliminary findings from its research in 1Q of 2022.
Price Action: ADGI shares are up 18.0% at $6.88 during the premarket session on the last check Thursday.